RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 41 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 41

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
  2. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  3. Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
  4. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  5. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  6. Study siteBeijing GoBroad Hospital北京高博医院BeijingHospital page
  7. Study siteCancer Hospital CAMS – Shenzhen中国医学科学院肿瘤医院深圳医院ShenzhenHospital page
  8. Study siteChanghai Hospital海军军医大学第一附属医院(长海医院)ShanghaiHospital page
  9. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  10. Study siteFifth Affiliated Hospital of Sun Yat-sen University中山大学附属第五医院ZhuhaiHospital page
  11. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  12. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  13. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  14. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  15. Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
  16. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  17. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  18. Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
  19. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  20. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  21. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  22. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  23. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  24. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  25. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  26. Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
  27. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  28. Study siteQingdao Central Hospital康复大学青岛中心医院QingdaoHospital page
  29. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  30. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  31. Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
  32. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  33. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  34. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  35. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  36. Study siteTangshan People's HospitalTangshanHospital page
  37. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  38. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  39. Study siteXi'an International Medical Center Hospital西安国际医学中心医院Xi'anHospital page
  40. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  41. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06210776, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06210776, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Patients must meet all of the following inclusion criteria to be eligible for the study:

  • ≥18 years of age at time of consent.
  • Pathologically documented breast cancer that is unresectable or metastatic.
  • Cohort A: Patients with confirmed HER2+ (IHC 3+ or IHC2+, ISH+); and patients have received one or more prior anti-HER2-based regimens; and patients should have received no more than 2 lines therapy in the metastatic settings.

Cohort B: Patients with confirmed HER2-low expression (IHC 1+ or IHC 2+, ISH-); and patients have received at least a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; and patients should have received no more than 2 lines of previous chemotherapy regimen in the metastatic settings.

  • Decision to newly initiate T-DXd or just have started the first dose no longer than 14 days after the index date per approved label in China.
  • Capable of providing informed consent.
  • Patients capable of completing questionnaires are preferred. If the participant is unable to complete the questionnaire (e.g., being blind, illiterate, not fluent in the available language, or ePRO system is not ready), that participant is exempted from completing PRO questionnaires but may still participate in the study.

Patients who meet any of the following criteria will be excluded from the study:

  • Pregnancy or breastfeeding.
  • Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded.
  • Patients who have known to have hypersensitivity reactions to the active substance of T-DXd or any excipients.
  • Patients who have been judged by the investigator to be unfit to participate the study.

Quoted from ClinicalTrials.gov, NCT06210776, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06210776, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06210776